SERB Pharmaceuticals: Company Research Report
Company Overview
Name
SERB Pharmaceuticals
Mission of the Company
SERB Pharmaceuticals aims to be a dedicated ally to healthcare providers treating patients with critical conditions. They focus on making treating complex and life-threatening conditions possible, supporting clinicians, healthcare systems, and governments, while offering hope to patients and their families.
Founded
- Year: 1951
- Original Name: Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research)
Key People
- Chairman: Jeremie Urbain
- CEO: Anthony Higham
Headquarters
No information is available on the exact location of the headquarters.
Number of Employees
470 dedicated employees
Revenue
No information is available.
Known For
SERB Pharmaceuticals is known for its broad portfolio of emergency care and rare disease medications. They have the largest antidote portfolio globally, which includes medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) risks.
Products
Overview
SERB Pharmaceuticals offers a vast array of products focused on emergency care and rare diseases. They have over 80 medicines supplied across more than 100 countries.
Product Details
1. RSDL® (Reactive Skin Decontamination Lotion)
- Category: Emergency care, Medical Device
- Description: Pre-impregnated foam sponge applicator pad for skin decontamination.
- Regions Available: AsiaPac, Canada, Europe (incl. UK), Middle East North Africa, US
2. Voraxaze®
- Active Ingredient: Glucarpidase 1000 units/vial
- Category: Antidote for emergency care and rare diseases
- Regions Available: AsiaPac, Europe (incl. UK), US
3. Cyanokit®
- Active Ingredient: Hydroxocobalamin 5g
- Category: Antidote for emergency care
- Regions Available: AsiaPac, Canada, Europe (incl. UK), Middle East North Africa, US
4. DigiFab®
- Active Ingredient: Digoxin immune Fab (ovine) - 40 mg/vial
- Category: Antidote for emergency care
- Regions Available: Canada, Europe (incl. UK), US
5. Aurlumyn™ (Iloprost IV)
- Indication: Severe frostbite
- Key Features: Only FDA-approved treatment option in the US for severe frostbite; prostacyclin mimetic that reduces the risk of digit amputations.
Recent Developments
New Products Launched
1. Aurlumyn™ (iloprost IV)
- Acquired in October 2024 for treating severe frostbite.
2. Bentracimab
- A biologics license application accepted by the FDA for priority review. It is the first and only ticagrelor reversal agent.
New Features and Partnerships
1. RSDL® Acquisition
- Strengthened leadership through acquisition for $75 million from Emergent BioSolutions Inc. in July 2024. It involves acquiring leased manufacturing facility operations in Hattiesburg, Mississippi.
2. Leadership Initiatives
- Appointed Vanessa Wolfeler as CEO to drive company growth.
3. Sustainability Initiatives
- Published its first Sustainability Report in April 2024, marking efforts to align with UN Sustainable Development Goals and covering ESG issues.
By focusing on critical care products and partnerships, SERB Pharmaceuticals has extended their global impact, ensuring clinically effective outcomes in emergency settings and rare diseases. They continue to expand their leadership through strategic acquisitions and fostering industry partnerships, maintaining their position as a critical player in healthcare provision.
